BridgeBio Pharma Other Long-Term Assets 2018-2025 | BBIO
BridgeBio Pharma other long-term assets from 2018 to 2025. Other long-term assets can be defined as field containing the sum of all non-current assets that cannot be standardized into another field as well as those that are aggregated by the company because materially, they are too small to list separately.
- BridgeBio Pharma other long-term assets for the quarter ending March 31, 2025 were $0.017B, a 19.85% decline year-over-year.
- BridgeBio Pharma other long-term assets for 2024 were $0.018B, a 19.58% decline from 2023.
- BridgeBio Pharma other long-term assets for 2023 were $0.023B, a 11.87% increase from 2022.
- BridgeBio Pharma other long-term assets for 2022 were $0.02B, a 38.77% decline from 2021.
BridgeBio Pharma Annual Other Long-Term Assets
(Millions of US $) |
| 2024 |
$18 |
| 2023 |
$23 |
| 2022 |
$20 |
| 2021 |
$33 |
| 2020 |
$24 |
| 2019 |
$26 |
| 2018 |
$1 |
| 2017 |
$0 |
BridgeBio Pharma Quarterly Other Long-Term Assets
(Millions of US $) |
| 2025-03-31 |
$17 |
| 2024-12-31 |
$18 |
| 2024-09-30 |
$20 |
| 2024-06-30 |
$19 |
| 2024-03-31 |
$21 |
| 2023-12-31 |
$23 |
| 2023-09-30 |
$19 |
| 2023-06-30 |
$20 |
| 2023-03-31 |
$21 |
| 2022-12-31 |
$20 |
| 2022-09-30 |
$30 |
| 2022-06-30 |
$31 |
| 2022-03-31 |
$35 |
| 2021-12-31 |
$33 |
| 2021-09-30 |
$33 |
| 2021-06-30 |
$50 |
| 2021-03-31 |
$30 |
| 2020-12-31 |
$24 |
| 2020-09-30 |
$16 |
| 2020-06-30 |
$17 |
| 2020-03-31 |
$17 |
| 2019-12-31 |
$26 |
| 2019-09-30 |
$3 |
| 2019-06-30 |
|
| 2019-03-31 |
|
| 2018-12-31 |
|
| 2018-09-30 |
|
| 2017-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$6.802B |
$0.222B |
|
BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States.
|
